Last reviewed 2026-05-23 · How we verify

Restalyne Silk

The Maas Clinic · FDA-approved active Small molecule Under review

Restalyne Silk is a Dermal filler Small molecule drug developed by The Maas Clinic. It is currently FDA-approved for Lip augmentation and enhancement, Perioral lines and wrinkles.

Restylane Silk is a hyaluronic acid-based dermal filler that adds volume and smoothness to the lips and perioral area by integrating into the dermis.

Restalyne Silk is a protein-based dermal filler used to treat superficial, vertical perioral lines. It is a type of silk fibroin, a protein modality, and has been studied in clinical trials for the treatment of perioral rhytids.

At a glance

Generic name	Restalyne Silk
Sponsor	The Maas Clinic
Drug class	Dermal filler
Target	Hyaluronic acid receptor (CD44)
Modality	Small molecule
Therapeutic area	Dermatology/Aesthetics
Phase	FDA-approved

Mechanism of action

Restylane Silk uses stabilized hyaluronic acid (a naturally occurring polysaccharide) to restore lost volume and enhance lip fullness and definition. The filler particles are smaller than standard Restylane, allowing for smoother integration into the dermis and a more natural appearance. It provides both immediate volumization and subtle contouring of the lips and surrounding perioral region.

Approved indications

Lip augmentation and enhancement
Perioral lines and wrinkles

Common side effects

Injection site swelling
Injection site bruising
Injection site redness
Injection site tenderness
Lip asymmetry

Key clinical trials

A Clinical Study Comparing Restylane® Silk and Belotero Balance® for the Treatment of Superficial, Vertical Perioral Lines (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Restalyne Silk CI brief — competitive landscape report
Restalyne Silk updates RSS · CI watch RSS
The Maas Clinic portfolio CI

Frequently asked questions about Restalyne Silk

What is Restalyne Silk?

Restalyne Silk is a Dermal filler drug developed by The Maas Clinic, indicated for Lip augmentation and enhancement, Perioral lines and wrinkles.

How does Restalyne Silk work?

Restylane Silk is a hyaluronic acid-based dermal filler that adds volume and smoothness to the lips and perioral area by integrating into the dermis.

What is Restalyne Silk used for?

Restalyne Silk is indicated for Lip augmentation and enhancement, Perioral lines and wrinkles.

Who makes Restalyne Silk?

Restalyne Silk is developed and marketed by The Maas Clinic (see full The Maas Clinic pipeline at /company/the-maas-clinic).

What drug class is Restalyne Silk in?

Restalyne Silk belongs to the Dermal filler class. See all Dermal filler drugs at /class/dermal-filler.

What development phase is Restalyne Silk in?

Restalyne Silk is FDA-approved (marketed).

What are the side effects of Restalyne Silk?

Common side effects of Restalyne Silk include Injection site swelling, Injection site bruising, Injection site redness, Injection site tenderness, Lip asymmetry.

What does Restalyne Silk target?

Restalyne Silk targets Hyaluronic acid receptor (CD44) and is a Dermal filler.

Drug class: All Dermal filler drugs
Target: All drugs targeting Hyaluronic acid receptor (CD44)
Manufacturer: The Maas Clinic — full pipeline
Therapeutic area: All drugs in Dermatology/Aesthetics
Indication: Drugs for Lip augmentation and enhancement
Indication: Drugs for Perioral lines and wrinkles

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing